Publications by authors named "Juliana Marilia Berretta"
Article Synopsis
- Neurodegeneration can change blood pressure and affect kidney function in Alzheimer's patients, making this study focus on how ACE inhibitors and statins influence cardiovascular risks based on genetic variations.
- The study involved tracking 193 patients for a year to see how different genetic markers impacted their responses to these medications, specifically looking at blood pressure and creatinine levels.
- Results showed that ACE inhibitors were effective in lowering blood pressure and improved kidney function in specific genetic carriers, while statins had a lesser impact, indicating that individual genetic makeup plays a key role in treatment responses for cardiovascular issues in Alzheimer's patients.
Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease.
Colomb Med (Cali)
June 2016
Background: Renal function declines according to age and vascular risk factors, whereas few data are available regarding genetically-mediated effects of anti-hypertensives over renal function.
Objective: To estimate urea and creatinine variations in dementia due to Alzheimer disease (AD) by way of a pharmacogenetic analysis of the anti-hypertensive effects of angiotensin-converting enzyme inhibitors (ACEis).
Methods: Consecutive outpatients older than 60 years-old with AD and no history of kidney transplant or dialytic therapy were recruited for prospective correlations regarding variations in fasting blood levels of urea and creatinine in one year, considering ACE genotypes of rs1800764 and rs4291 and their respective haplotypes, and treatment with ACEis along with blood pressure variations.